Global Collaboration Action for the Development of Vaccines for Reducing the Disease

The objective of the topic is to progress the development of vaccine candidates under development and licensed TB vaccines, especially targeting the population in low-middle countries, particularly in SSA.

Proposals should carry out early and/or late-stage clinical studies to evaluate the safety, immunogenicity, efficacy and/or clinical utility on vaccine candidates under development and licensed vaccines in SSA. Proposals are to generate clinical data on TB prophylactic vaccines in adults and adolescents, and including where appropriate, pregnant and lactating women, new-borns, children, other vulnerable and neglected populations, and people with co-infections and co-morbidities at risk in SSA when relevant. A comparative arm with BCG and an assessment of overall health outcomes may be included when appropriate.

Expected Outcomes

• This topic aims at supporting activities that contribute to one or several of the expected impacts for this call. To that end, proposals submitted under this topic should aim for delivering results that are directed, tailored towards and contributing to at least two of the following expected outcomes, with the first being mandatory:
  • Obtain evidence of immunogenicity, efficacy, safety or clinical utility on vaccine candidates under development and licensed vaccine(s);
  • Generate clinical data on TB prophylactic vaccines serving adolescents and adults, and including where appropriate pregnant and lactating women, new-borns, children, other vulnerable and neglected populations, and people with co-infections and co-morbidities at risk in SSA;
  • Contribute to the data package related to immunisation/vaccination enabling public health authorities and policy makers to recommend on vaccination strategies, publish updated or new evidence-based clinical guidelines and best practices or design tailor-made TB policies targeting SSA.

Eligible Projects

• The scientific project leader should indicatively perform the following tasks:
  • During the call for proposals and selection process, coordinate meetings on and drafting of the full project proposal;
  • Work with the coordinator and other beneficiaries on the drafting and negotiation of the consortium agreement and other legal agreements among the beneficiaries;
  • Act as the key contact point for the Global Health EDCTP3 JU regarding all scientific action governance issues, steer and provide oversight in the development of the scientific actions, without prejudice to the tasks entrusted directly to the coordinator as per the Model Grant Agreement;
  • Support and collaborate with the coordinator on its monitoring activities and the adoption of appropriate internal measures, to ensure that beneficiaries are fulfilling their obligations regarding budget, timeline, deliverables, and scientific quality;
  • Review the action’s deliverables and reports before their submission by the coordinator;
  • Lead the work packages(s) related to the tasks of scientific project leadership.

Beneficiaries

• Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of the Global Health EDCTP3 JU, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes as beneficiaries:
  • At least three legal entities independent from each other and each established in a different country, where legal entities are eligible to receive funding;
  • At least one independent legal entity established in a Member State, or in an associated country to Horizon Europe that is a member of the EDCTP Association; and
  • At least one independent legal entity established in a sub-Saharan African country that is a member of the EDCTP Association.

For more information, visit European Commission.